Get the Facts on Anti-Competitive Practices among PBMs
Health plans and their PBMs attribute the excessive growth of DIR fees to pharmacy performance assessments, but the assessments and metrics lack transparency, are arbitrary, and have no oversight. Representing 12,000 grocery pharmacies across the nation, FMI wants to put a stop to the predatory practice of imposing fees on pharmacies long after the point of sale while charging patients more up front for their drugs. Our goal is to create pricing transparency through legislation for both pharmacies and their patients.